On May 27, 2020, Heat Biologics announced a collaboration with Waisman Biomanufacturing to establish a partnership for the manufacture of Heat’s COVID-19 vaccine. Waisman specializes in the manufacture of cellular therapeutics and other biologics for early-stage clinical trials and is part of the University of Wisconsin, Madison. To date, it has manufactured over 320 clinical grade products, earning a reputation for cost-effective and timely production of quality biologics.